<DOC>
	<DOCNO>NCT01219543</DOCNO>
	<brief_summary>This Phase I , open-label dose escalation study evaluate safety tolerability AZD1480 ( JAK2 inhibitor ) Asian patient advance solid tumor ( Part A C ) patient advanced HCC ( Part B ) escalation phase , EGFR ROS mutant NSCLC non-smokers lung metastasis gastric cancer expansion phase evaluate daily BID dosing .</brief_summary>
	<brief_title>A Phase I Study AZD1480 Patients With Advanced Solid Malignancies Advanced Hepatocellular Carcinoma Escalation Phase , Non-Small Cell Lung Cancer ( NSCLC ) Non-smokers With Lung Metastasis Gastric Cancer Solid Tumour Expansion Phase .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Male female age 18 year old For Part A C : Histological cytological confirmation solid malignant tumour refractory standard therapy standard therapy exist . Patients lymphoma &amp; HCC exclude . For Expansion : Histological cytological confirmation Expansion 1 : EGFR and/or ROS mutant NSCLC Nonsmokers lung metastasis Expansion 2 : Gastric cancer solid tumour biopsy available ( consent pair biopsy ) refractory standard therapy standard therapy exist . Patients lymphoma &amp; HCC exclude . For Part B : Advanced metastatic HCC , unresectable incurable ablative therapy TACE , standard therapy available . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 deterioration previous 2 week For Part B : ChildPugh liver function status classify A B7 For chemotherapy , immunotherapy anticancer agent , within 5 half live 3 week must elapse treatment first dose investigational product , whichever short . With exception alopecia , unresolved toxicity prior therapy â‰¥ Grade 2 CTCAE V4.02 time start study ( except LFTs HCC patient , may Grade 2 time start study ) Any follow condition : Interferon treatment HBV HCV Prior Liver Transplantation Inadequate bone marrow reserve organ function demonstrate laboratory value Evidence establish interstitial lung disease ( ILD ) baseline high resolution computerize tomography ( HRCT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Advanced solid malignancy</keyword>
	<keyword>Child-Pugh A B7 advance hepatocellular carcinoma</keyword>
	<keyword>EGFR and/or ROS mutant NSCLC</keyword>
	<keyword>Non-smokers lung metastasis</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Solid tumour</keyword>
	<keyword>AZD1480</keyword>
	<keyword>JAK1/JAK2 kinase inhibitor</keyword>
</DOC>